Lofexidine Tablet, Coated
Product Images NDC 14445-146

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lofexidine (NDC 14445-146). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Indoco Remedies Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lofexidine-structure (Lofexidien Structure)

Chemical structure of lofexidine hydrochloride, showing a chlorine-substituted aromatic ring attached to an imidazoline moiety with a hydrochloride component.*

FDA Label Image

Carton-label-96 (Lofexidine Carton Label)

Packaging label for Lofexidine Tablets 0.18 mg oral coated tablets by Indoco Remedies Limited. The carton displays dosage strength (0.18 mg), NDC 14445-146, storage instructions, and safety warnings. It indicates a package count of 96 tablets and manufacturer information including address in Verna, Goa.*

FDA Label Image

Container-label-96 (Lofexidine Container Label)

Lofexidine Tablets 0.18 mg oral coated tablet label from Indoco Remedies Limited. The label includes the NDC 14445-146, notes the prescription-only status, and contains storage instructions to keep at 25°C with allowed excursions. The package contains 96 tablets and advises keeping the bottle tightly closed and out of reach of children.*

FDA Label Image

Lofexidine-fig-1 (Lofexidine Fig 1)

A Kaplan-Meier survival curve chart showing the proportion of subjects completing treatment over study days 1 to 7. The chart compares three groups: Lofexidine 2.16 mg, Lofexidine 2.88 mg, and Placebo, with the y-axis representing the proportion of subjects completing the treatment period and the x-axis representing study days.*

FDA Label Image

Lofexidine-fig-2 (Lofexidine Fig 2)

A line graph depicting mean SOWS-Gossop scores over a 7-day study period, comparing Lofexidine dosages of 2.16 mg and 2.88 mg versus placebo. The graph includes error bars representing 95% confidence intervals for each group.*

FDA Label Image

Lofexidine-fig-3 (Lofexidine Fig 3)

A Kaplan-Meier survival curve comparing the proportion of subjects completing a treatment period over 8 days for Lofexidine 2.88 mg versus placebo. The x-axis represents study days from 1 to 8, and the y-axis shows the proportion of subjects completing treatment, ranging from 0 to 1. A solid line indicates Lofexidine, and a dashed line indicates placebo.*

FDA Label Image

Lofexidine-fig-4 (Lofexidine Fig 4)

A line graph comparing mean SWS Gossop scores over five study days for Lofexidine 2.88 mg and placebo groups. The y-axis represents mean SWS Gossop scores, and the x-axis represents study days from 1 to 5. The graph includes 95% confidence intervals for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.